SEPT9 was initially identified in treatment-related acute myeloid leukemia as a fusion partner of the histone methyltransferase Mixed-Lineage Leukemia (MLL) and hence named MLL Septin-like Fusion (MSF) [18]. This evidence concerns the gene KMT2A and acute myeloid leukemia.